# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-Reuters
Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q2 sales of $71.55 million. Earnings fell to a loss of $82....
Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $71.55 million during Q2 according to data provided by Benzing...
Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings:
Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings:
RBC Capital analyst Gregory Renza downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Sector Perform and ra...